Microporous Polysaccharide Hemospheres Epistaxis

Overview

The purpose of this study is to compare a new treatment for nosebleeds to the treatment that has been used for many years.

Full Title of Study: “Use of Microporous Polysaccharide Hemospheres (MPH) in Management of Acute Epistaxis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2015

Detailed Description

Nosebleeds are a common condition which affect many Americans every day.The standard treatment in this hospital for nosebleeds that do not resolve with squeezing the nose or nasal spray is to place a nasal packing (aka nasal tampon) into the nose. This is an effective treatment in most cases, but patients may find it to be uncomfortable. The investigators will be comparing the standard nasal packing with a new type of powder which may also stop nosebleeds.

Interventions

  • Device: Microporous Polysaccharide Hemospheres
    • Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
  • Device: Nasal Tampon
    • 8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.

Arms, Groups and Cohorts

  • Active Comparator: Microporous Polysaccharide Hemospheres (MPH)
    • Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
  • Active Comparator: Merocel (Control)
    • Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.

Clinical Trial Outcome Measures

Primary Measures

  • Number of subjects with resolution of bleed
    • Time Frame: 15 minutes (average time to resolve bleeding)
    • Resolution of bleeding is determined by cessation of blood flow anteriorly from the nares as well as posteriorly in the pharynx. This will be determined by the otolaryngology resident or attending managing the patient during the study.

Secondary Measures

  • Time until resolution of bleeding
    • Time Frame: 15 minutes (average time to resolve bleeding)
    • Number of minutes it takes to resolve bleeding comparing the Arista powder group versus the Merocel tampon group.

Participating in This Clinical Trial

Inclusion Criteria

  • acute epistaxis who have failed conservative measures (including application of pressure and application of oxymetazoline spray) and for which the Otolaryngology service has been consulted – must be alert and oriented – hemodynamically stable with a hemoglobin greater than 9 g/dL – cooperative Exclusion Criteria:

  • unable to consent or cooperate – history of hereditary hemorrhagic telengectasias – hemophilia – clotting factor deficiencies – history of prior surgery for epistaxis control – nasal trauma – recent sinonasal surgery – hemodynamic instability – posterior bleed (as determined by Ear, Nose, Throat physician) – visibly bleeding vessel – allergy to product – current diabetic ketoacidosis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Emory University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Oswaldo A Henriquez, Principal Investigator – Emory University
  • Overall Official(s)
    • Oswaldo Henriquez Ajami, MD, Principal Investigator, Emory University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.